Testing a new oral vaccine to prevent shigella and ETEC infection
Part of Digestive system, Infections clinical trials.
This trial tests an oral vaccine designed to protect against two common causes of severe diarrhea: shigella and ETEC bacteria. Healthy adults aged 18 to 50 will receive the vaccine and later be exposed to the bacteria to see if it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 50 years old and generally healthy.
- You have not had a lab-confirmed shigella or ETEC infection in the last 5 years.
- You do not have a chronic stomach or bowel condition, and have not had major bowel surgery.
- You are not taking antibiotics, probiotics, or acid-reducing medications currently or in the last week.
- You do not live with a child under 2 years old or someone with a weakened immune system.
- You are willing to stay in the clinic for part of the study and not smoke during that time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new Shigella vaccine in healthy adults to see if it is safe and creates a good immune response. It is a first-in-human study, meaning this is the first time the vaccine is given to people.
This study tests how well a recommended treatment works for children aged 6 months to 5 years who have diarrhea caused by Shigella bacteria. It aims to find the best way to help children recover faster.
This study gives (or follows) typhoid and/or cholera vaccines and measures how your immune system responds. It is done in adults who are already scheduled for an upper endoscopy (EGD) and/or colonoscopy, using small tissue samples if appropriate.
This Phase 1 study tests a Shigella (gut infection) vaccine and additives to see how safe they are in healthy adults. If you qualify, you may help researchers understand whether the vaccine triggers any unwanted immune or stomach side effects.
This trial tests a new vaccine called IP-QSV to see if it is safe and creates an immune response against Shigella bacteria, a common cause of diarrhea. It is for healthy adults, adolescents, children, and infants.
This Phase 1 study gives a carefully measured dose of Shigella sonnei to healthy adults to learn about the infection’s safety and how the body responds. It may help researchers build safer future tests or treatments, but it requires a hospital stay and many follow-up visits.
Hear when a new Shigella trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.